<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>J&amp;J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned? — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">J&amp;J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?</h2>
    <div class="badge">2025-09-08T13:15:00+00:00</div>
    <ul>
      <li>AbbVie’s oncology segment generated combined revenues of $3.3 billion in the first half of 2025, up 4.2% year over year, as higher sales of Venclexta and contributions from new drugs, Elahere and Epkinly, more than offse</li>
<li>Stelara sales declined 38.6% in the first half of 2025.</li>
<li>It expects the Innovative Medicine business to grow 5% to 7% from 2025 to 2030.</li>
<li>The Zacks Consensus Estimate for J&amp;J’s 2025 sales and EPS implies a year-over-year increase of 5.2% and 8.8%, respectively.</li>
<li>Sales of its neuroscience drugs increased 20.3% to almost $5 billion in the first half of 2025, driven by higher sales of Botox Therapeutic, depression drug Vraylar and newer migraine drugs Ubrelvy and Qulipta.</li>
<li>Skyrizi and Rinvoq generated combined sales of $11.6 billion in the first half of 2025.</li>
<li>JNJ Estimate Movement Image Source: Zacks Investment Research The Zacks Consensus Estimate for AbbVie’s 2025 sales and EPS implies a year-over-year increase of 7.5% and 18.9%, respectively.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=J&amp;amp;J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?\n• AbbVie’s oncology segment generated combined revenues of $3.3 billion in the first half of 2025, up 4.2% year over year, as higher sales of Venclexta and contributions from new drugs, Elahere and Epkinly, more than offse\n• Stelara sales declined 38.6% in the first half of 2025.\n• It expects the Innovative Medicine business to grow 5% to 7% from 2025 to 2030.\n• The Zacks Consensus Estimate for J&amp;J’s 2025 sales and EPS implies a year-over-year increase of 5.2% and 8.8%, respectively.\n• Sales of its neuroscience drugs increased 20.3% to almost $5 billion in the first half of 2025, driven by higher sales of Botox Therapeutic, depression drug Vraylar and newer migraine drugs Ubrelvy and Qulipta.\n• Skyrizi and Rinvoq generated combined sales of $11.6 billion in the first half of 2025.\n• JNJ Estimate Movement Image Source: Zacks Investment Research The Zacks Consensus Estimate for AbbVie’s 2025 sales and EPS implies a year-over-year increase of 7.5% and 18.9%, respectively." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/j-j-vs-abbvie-healthcare-131500100.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>